Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanjivani Paranteral reported significantly weakened Q4 FY26 performance with revenue falling 42.2% year-on-year to INR 105.1 million. Full-year FY26 revenue declined 7.6% to INR 647.6 million. PAT for the quarter dropped 57.3% to INR 9.4 million, while full-year PAT fell 14.5% to INR 69.2 million. EBITDA margins compressed to 14.7% in Q4 from 16.4% in the prior year, indicating profitability pressure. The company is primarily an injectable-focused CDMO with ~85% export revenue. Management outlined four growth drivers: expanding product portfolio, entering new geographies, therapeutic diversification, and strategic partnerships. The presentation contains no explicit forward guidance or multi-year targets.
The sharp Q4 decline and full-year revenue contraction signal operational challenges, likely from client order timing or market headwinds in export markets. Compressed margins add further concern. Shareholders should monitor the company's recovery path and whether the stated growth initiatives translate into improved financials.